Skip to content

C93.02 ICD-10-CM Code: Acute monoblastic/monocytic leukemia, in relapse

C93.02 maps to CMS-HCC V28 17. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC coding software

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC93.02

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C93.02

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Acute monoblastic/monocytic leukemia, in relapse

An acute blood cancer affecting monocyte-forming cells that has returned after a period of remission.

Buddy the Bee presenting code insight

Buddy Insight

Acute monoblastic/monocytic leukemia in relapse represents one of the most clinically challenging scenarios, as recurrent monocytic leukemia often shows increased resistance to chemotherapy.

CMS-HCC V28

HCC 17

Coefficient HCC 17: 4.209 (Community Non-Dual Aged (CNA))

CMS-HCC V24

Historical

Historical

Not used for CY2026 payment

ACA/HHS

HCC 008

Code-level coefficient reference

ESRD/PACE

HCC 8

Code-level coefficient reference

RXHCC

HCC 19

Code-level coefficient reference

Inclusion Terms

Official
  • AML M5Inherited from C93.0
  • AML M5aInherited from C93.0
  • AML M5bInherited from C93.0

Excludes 2

Official
  • Kaposi's sarcoma of lymph nodes (C46.3)Inherited from C81-C96
  • secondary and unspecified neoplasm of lymph nodes (C77.-)Inherited from C81-C96
  • secondary neoplasm of bone marrow (C79.52)Inherited from C81-C96
  • secondary neoplasm of spleen (C78.89)Inherited from C81-C96

Includes

Official
  • monocytoid leukemiaInherited from C93

Excludes 1

Official
  • personal history of leukemia (Z85.6)Inherited from C93

Code First

Official

No Code First sequencing instructions are included in this display for C93.02. Check the code and parent instructions in the Code Book.

Use Additional

Official

No Use Additional Code instructions are included in this display for C93.02. Check the code and parent instructions in the Code Book.

Code Also

Official

No Code Also instructions are included in this display for C93.02. Check the code and parent instructions in the Code Book.

Buddy Documentation Tip

HCC Buddy guidance
Documentation must establish prior remission before coding relapse, including dates and clinical evidence.
Current relapse documentation should include blast percentage on bone marrow biopsy, peripheral blood findings, any extramedullary disease involvement, and the salvage treatment plan being considered or initiated.

MEAT Support

HCC Buddy guidance
Documentation must establish prior remission before coding relapse, including dates and clinical evidence.
Current relapse documentation should include blast percentage on bone marrow biopsy, peripheral blood findings, any extramedullary disease involvement, and the salvage treatment plan being considered or initiated.

Audit Caution

HCC Buddy guidance
Relapse and primary refractory disease are clinically distinct and require different codes.
Verify the documented timeline shows remission was achieved before recurrence.
The time interval between remission and relapse is prognostically significant and should be captured in documentation.

Common Mistakes

HCC Buddy guidance
C93.00 (not achieved remission) applies when initial treatment failed, not when disease recurs.
C93.01 (in remission) is the pre-relapse state.
C92.02 (acute myeloblastic leukemia in relapse) is a different leukemia subtype and should not be confused with monoblastic/monocytic subtypes.

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C93.02 an HCC code?

Yes. C93.02 (Acute monoblastic/monocytic leukemia, in relapse) maps to HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 4.209. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C93.02 is billable and maps to V28 HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code
C93.02
Description
Acute monoblastic/monocytic leukemia, in relapse
HCC (V28)
HCC 17 — Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
RAF reference coefficient
4.209
Billable
Yes
Payment year
2026

HCC Category Mapping

V28HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
4.209
ESRDHCC 8, Metastatic Cancer and Acute Leukemia
Not separately weighted
RxHCCHCC 19, Leukemias and Other Hematologic Cancers
Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C93.02 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for C93.02

For C93.02, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C93.02 is the ICD-10-CM diagnosis code for acute monoblastic/monocytic leukemia, in relapse. An acute blood cancer affecting monocyte-forming cells that has returned after a period of remission. C93.02 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C93.02 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic (HCC 17) with a source-labeled community, non-dual, aged reference coefficient of 4.209. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

The '2' suffix indicates relapse; verify documentation shows prior remission before the current recurrence. For C93.02, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C93.02 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • The '2' suffix indicates relapse; verify documentation shows prior remission before the current recurrence
  • Document the time interval between remission and relapse, as this affects prognosis and treatment planning

Clinical Significance

Acute monoblastic/monocytic leukemia in relapse represents one of the most clinically challenging scenarios, as recurrent monocytic leukemia often shows increased resistance to chemotherapy. Relapsed disease frequently requires more aggressive salvage regimens, including consideration for allogeneic stem cell transplantation.

Documentation Requirements

  • Documentation must establish prior remission before coding relapse, including dates and clinical evidence.
  • Current relapse documentation should include blast percentage on bone marrow biopsy, peripheral blood findings, any extramedullary disease involvement, and the salvage treatment plan being considered or initiated.

Commonly Confused Codes

  • C93.00 (not achieved remission) applies when initial treatment failed, not when disease recurs.
  • C93.01 (in remission) is the pre-relapse state.
  • C92.02 (acute myeloblastic leukemia in relapse) is a different leukemia subtype and should not be confused with monoblastic/monocytic subtypes.

Child Codes

Code Hierarchy

Also searched as

  • C93 02
  • C9302

For C93.02, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

C93.02 maps to CMS-HCC V28 category 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. See the ICD-10 to HCC mapping hub for how the V28 crosswalk works. The mapping identifies a payment HCC category for C93.02. Review its source-labeled HCC coefficient above, check the RAF Calculator with complete member context for CMS-HCC V28 PY2026, and confirm the documentation the chart needs before the code is submitted. HCC Buddy shows no RAF score unless every required source and calculation check passes.

Work C93.02 in HCC Buddy

Open C93.02 in the Code Book for the full Index-to-Tabular path, MEAT checklist, and V28 HCC mapping, or in the Encoder to code from a keyword search. Pro includes 7 days to try everything, no card required.